Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 3,601–3,700 of 10,906
Nia, A. B. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab061 · Cited by 23
Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases
Iyer, S., Yadav, R. T., Agarwal, S., Tripathi, S., & Agarwal, R. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00123-21 · Cited by 23
The top 100 most cited articles on COVID-19 vaccine: a bibliometric analysis
Wang, W., Wang, H., Yao, T., Li, Y., Yi, L., Gao, Y., Lian, J., Feng, Y., & Wang, S. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01046-9 · Cited by 23
Khan, N. T., Zinnia, M. A., & Islam, A. B. M. M. K. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.2024253 · Cited by 20
Vress, D. (2021) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2021.03.009 · Cited by 19
Bennett, C., Woo, W., Bloch, M., Cheung, K., Griffin, P., Mohan, R., Deshmukh, S., Arya, M., Cumming, O., Neville, A. M., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00077-x · Cited by 22
Germinal centre-driven maturation of B cell response to SARS-CoV-2 vaccinationPreprint
Kim, W., Zhou, J. Q., Sturtz, A. J., Horvath, S. C., Schmitz, A. J., Lei, T., Kalaidina, E., Thapa, M., Alsoussi, W. B., Haile, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.31.466651 · Cited by 18
Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern
Chaouat, A. E., Brizić, I., Brlić, P. K., Atari, N., Kliker, L., Alfi, O., Mandelboim, M., Wolf, D. G., Tafish, L., Kol, I., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104935 · Cited by 17
Park, W. B., Hwang, Y. H., & Cheong, H. J. (2023) · Infection and Chemotherapy · doi:10.3947/ic.2023.0023 · Cited by 19
COVID-19 vaccination and the risk of swellings in patients with hereditary angioedema
Fijen, L. M., Levi, M. M., & Cohn, D. M. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.08.039 · Cited by 21
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
Rouhani, S. J., Yu, J., Olson, D. J., Zha, Y., Pezeshk, A., Cabanov, A., Pyzer, A. R., Trujillo, J., Derman, B. A., O’Donnell, P. H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004766 · Cited by 22
Bianchi, J., Hirt, J., Vogt, M., & Vetsch, J. (2025) · Cochrane Evidence Synthesis and Methods · doi:10.1002/cesm.70033 · Cited by 19
Perceptions of COVID ‐19 vaccines among healthcare assistants: A national survey
Niznik, J. D., Harrison, J., White, E. M., Syme, M. L., Hanson, L. C., Kelley, C. J., Porter, L., & Berry, S. D. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17437 · Cited by 22
Crombé, A., Bensid, L., Seux, M., Fadli, D., Arnaud, F., Benhamed, A., Banaste, N., & Gorincour, G. (2023) · Radiology · doi:10.1148/radiol.222730 · Cited by 19
Shrivastava, S., Carmen, J. M., Lu, Z., Basu, S., Sankhala, R. S., Chen, W., Nguyen, P., Chang, W. C., King, J., Corbitt, C., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00638-6 · Cited by 20
Otto, M., Burrell, A. J. C., Neto, A. S., Alliegro, P. V., Trapani, T. V., Cheng, A., Udy, A. A., & the SPRINT‐SARI Australia Investigators (2022) · Internal Medicine Journal · doi:10.1111/imj.15884 · Cited by 23
Efrati, S., Catalogna, M., Hamad, R. A., Hadanny, A., Bar‐Chaim, A., Benveniste‐Levkovitz, P., & Levtzion‐Korach, O. (2021) · Scientific Reports · doi:10.1038/s41598-021-96129-6 · Cited by 20
Sobczak, M., & Pawliczak, R. (2022) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-022-00525-3 · Cited by 20
Graves’ Disease Following SARS-CoV-2 Vaccination: A Systematic Review
Patrizio, A., Ferrari, S. M., Elia, G., Ragusa, F., Paparo, S. R., Mazzi, V., Antonelli, A., & Fallahi, P. (2022) · Vaccines · doi:10.3390/vaccines10091445 · Cited by 23
Low, J. G., de Alwis, R., Chen, S., Kalimuddin, S., Leong, Y. S., Mah, T. K. L., Yuen, N., Tan, H. C., Zhang, S. L., Sim, J. X. Y., et al. (2021) · doi:10.1101/2021.07.01.21259831 · Cited by 19
The Fundamental Flaws of the CNBSS Trials: A Scientific Review
Seely, J. M., Eby, P. R., & Yaffe, M. J. (2022) · Journal of Breast Imaging · doi:10.1093/jbi/wbab099 · Cited by 19
Rifai, M. A., Khalid, U., Misra, A., Liu, J., Nasir, K., Cainzos‐Achirica, M., Mahtta, D., Ballantyne, C. M., Petersen, L. A., & Virani, S. S. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100150 · Cited by 19
Saharia, K., Anjan, S., Streit, J. A., Beekmann, S. E., Polgreen, P. M., Kuehnert, M. J., Segev, D. L., Baddley, J. W., Miller, R. A., & the EIN COVID‐19 Study Team (2022) · Transplant Infectious Disease · doi:10.1111/tid.13774 · Cited by 20
A Review of Different Vaccines and Strategies to Combat COVID-19
Sabitha, S., Shobana, N., Prakash, P., Padmanaban, S., Sathiyasree, M., Saigeetha, S., Chakravarthi, S., Uthaman, S., Park, I., & Samrot, A. V. (2022) · Vaccines · doi:10.3390/vaccines10050737 · Cited by 30
Banerjee, A., Lew, J. M., Kroeker, A., Baid, K., Aftanas, P., Nirmalarajah, K., Maguire, F., Kozak, R. A., McDonald, R. R., Lang, A. L. S., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.002 · Cited by 19
Baldolli, A., Michon, J., Appia, F., Galimard, C., Verdon, R., & Parienti, J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.054 · Cited by 19
Vacinação do Cardiopata contra COVID-19: As Razões da Prioridade
Martins, W. D. A., de Oliveira, G. M. M., Brandão, A. A., Mourilhe‐Rocha, R., Mesquita, E. T., Saraiva, J. F. K., Bacal, F., & Lopes, M. A. C. Q. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210012 · Cited by 34
Fang, Y., Ma, B., Zhao, Z., Xuan, Z., Wang, Y., Huang, C., Zhang, M., Zhou, L., Feng, Y., Li, K., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07897 · Cited by 23
Vernet, R., Charrier, E., Grogg, J., & Mach, N. (2021) · Vaccines · doi:10.3390/vaccines9070770 · Cited by 19
The Value of Rapid Antigen Tests for Identifying Carriers of Viable SARS-CoV-2
Shidlovskaya, E. V., Kuznetsova, N. A., Divisenko, E. V., Nikiforova, M. A., Siniavin, A. E., Ogarkova, D. A., Shagaev, A. V., Semashko, M. A., Петрович, Т. А., Burgasova, O., et al. (2021) · Viruses · doi:10.3390/v13102012 · Cited by 18
Hao, X., Zhang, Z., Ma, J., Cheng, L., Ji, Y., Liu, Y., Zhao, D., Zhang, W., Li, C., Li, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.983505 · Cited by 20
A decavalent composite mRNA vaccine against both influenza and COVID-19
Wang, Y., Ma, Q., Li, M., Mai, Q., Ma, L., Zhang, H., Zhong, H., Mai, K., Cheng, N., Feng, P., et al. (2024) · mBio · doi:10.1128/mbio.00668-24 · Cited by 20
Bordeaux, S. J., Baca, A. W., Begay, R. L., Gachupin, F. C., Caporaso, J. G., Herbst‐Kralovetz, M. M., & Lee, N. (2021) · Current Oncology · doi:10.3390/curroncol28050316 · Cited by 21
Chen, Y., Zhang, L., Li, T., & Li, L. (2022) · BMC Public Health · doi:10.1186/s12889-022-14592-w · Cited by 18
Choi, M. J., Na, Y., Hyun, H., Nham, E., Yoon, J. G., Seong, H., Seo, Y. B., Choi, W. S., Song, J. Y., Kim, D. W., et al. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.12.010 · Cited by 23
Lipid nanoparticle steric stabilization roadmap
Cai, X., Zhai, J., Tran, N. L., Mulet, X., & Drummond, C. J. (2022) · Advances in biomembranes and lipid self-assembly · doi:10.1016/bs.abl.2022.05.003 · Cited by 22
Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain
AlQahtani, M., Du, X., Bhattacharyya, S., Alawadi, A., Mahmeed, H. A., Sayed, J. A., Justman, J. E., El‐Sadr, W., Hidary, J. D., & Mukherjee, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-12543-4 · Cited by 21
Duerr, R., Dimartino, D., Marier, C., Zappile, P., Wang, G., François, F., Ortigoza, M. B., Iturrate, E., Samanovic, M. I., Mulligan, M. J., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104843 · Cited by 20
Yu, Z., Zhu, X., Liu, X., Chen, X., Wei, T., Yuan, H.-Y., Xu, Y., Zhu, R., He, H., Wong, M. S., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147494 · Cited by 21
Bahmanyar, E. R., Out, H. J., & van Duin, M. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.03.024 · Cited by 21
Chung, W., Preclaro, I. A. C., Chung, W., & Wang, C. (2022) · Biomedicines · doi:10.3390/biomedicines10061260 · Cited by 23
Zhu, D. Y., Gorman, M. J., Yuan, D., Yu, J., Mercado, N. B., McMahan, K., Borducchi, E. N., Lifton, M. A., Liu, J., Nampanya, F., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001609 · Cited by 19
Microfluidics-Assembled Nanovesicles for Nucleic Acid Delivery
Li, X., Qin, Z., Wang, S., Zhang, L., & Jiang, X. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.4c00738 · Cited by 21
The race for a COVID-19 vaccine: where are we up to?
Hossain, M. K., Hassanzadeganroudsari, M., Feehan, J., & Apostolopoulos, V. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2021074 · Cited by 17
Reeg, D. B., Hofmann, M., Neumann‐Haefelin, C., Thimme, R., & Luxenburger, H. (2023) · Pathogens · doi:10.3390/pathogens12020244 · Cited by 23
Richmond, P., Hatchuel, L., Pacciarini, F., Hu, B. T., Smolenov, I. V., Li, P., Liang, P., Han, H. H., Liang, J. G., & Clemens, R. L. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab447 · Cited by 18
SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review
Sun, Y., Huang, W., Xiang, H., & Nie, J. (2024) · Vaccines · doi:10.3390/vaccines12050554 · Cited by 22
Lin, D.-Y., Gu, Y., Wheeler, B., Young, H., Holloway, S. T., Sunny, S. K., Moore, Z., & Zeng, D. (2021) · medRxiv · doi:10.1101/2021.10.25.21265304 · Cited by 19
Ramos, A., Cardoso, M. J., Ribeiro, L., & Guimarães, J. T. (2022) · Diagnostics · doi:10.3390/diagnostics12010205 · Cited by 20
Casas, I., & Mena, G. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.03.001 · Cited by 33
Tyrkalska, S. D., Candel, S., Pedoto, A., García‐Moreno, D., Alcaraz‐Pérez, F., Sánchez‐Ferrer, Á., Cayuela, M. L., & Mulero, V. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuac042 · Cited by 20
Kelliher, M. T., Levy, J., Nerenz, R. D., Poore, B. A., Johnston, A. A., Rogers, A. R., Stella, M. E. O., Snow, S. E., Cervinski, M. A., & Hubbard, J. A. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0607-sa · Cited by 18
Harnessing NKT cells for vaccination
Burn, O. K., Pankhurst, T. E., Painter, G. F., Connor, L. M., & Hermans, I. F. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab013 · Cited by 19
Durability of Protection Post–Primary COVID-19 Vaccination in the United States
Zheutlin, A. B., Ott, M. Q., Sun, R., Zemlianskaia, N., Meyer, C. S., Rubel, M., Hayden, J., Neri, B., Kamath, T. V., Khan, N. S., et al. (2022) · Vaccines · doi:10.3390/vaccines10091458 · Cited by 20
Predictors of Nonseroconversion to SARS-CoV-2 Vaccination in Kidney Transplant Recipients
Frölke, S. C., Bouwmans, P., Messchendorp, A. L., Geerlings, S. E., Hemmelder, M. H., Gansevoort, R. T., Hilbrands, L. B., Reinders, M. E. J., Sanders, J., Bemelman, F. J., et al. (2022) · Transplantation Direct · doi:10.1097/txd.0000000000001397 · Cited by 17
Jayagobi, P. A., Ong, C., Yeo, K. T., Lim, C. C. W., Seet, M. J., Kwek, L. K., Ku, C. W., Chan, J. K. Y., Mathur, M., & Chua, M. C. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2021-259 · Cited by 33
Napuri, N., Curcio, D., Swerdlow, D. L., & Srivastava, A. K. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00648-2 · Cited by 21
Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity
Ford, B. N., & Savitz, J. B. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00288-7 · Cited by 19
Alonso, R. N., Chertcoff, A. S., Leguizamón, F., Galleguillos, L., Eizaguirre, M. B., Rodríguez, R., Sosa, M., Carballido, S., Muñoz, V. C., de Jong-Martis, A., et al. (2021) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173211061543 · Cited by 19
Liu, Z., Wang, Q., Feng, Y., Zhao, L., Dong, N., Zhang, Y. X., Yin, T., He, H., Tang, X., Gou, J., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.146474 · Cited by 19
Fujii, S., Yamasaki, S., Iyoda, T., & Shimizu, K. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00239-1 · Cited by 18
Efficient mRNA Delivery with mRNA Lipoplexes Prepared Using a Modified Ethanol Injection Method
Tang, M., Sagawa, A., Inoue, N., Torii, S., Tomita, K., & Hattori, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041141 · Cited by 23
Huang, P., Liu, T., Wu, J., Tsai, Y., & Lai, C. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28621 · Cited by 20
Challenges and Opportunities for Osteoporosis Care During the COVID-19 Pandemic
CROMER, S. J., & Yu, E. W.-Y. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab570 · Cited by 22
Previously infected vaccinees broadly neutralize SARS-CoV-2 variantsPreprint
Leier, H. C., Bates, T. A., Lyski, Z. L., McBride, S. K., Lee, D. X., Coulter, F. J., Goodman, J. R., Lu, Z., Curlin, M. E., Messer, W. B., et al. (2021) · medRxiv · doi:10.1101/2021.04.25.21256049 · Cited by 19
A case of acquired haemophilia A in a 70‐year‐old post COVID‐19 vaccine
Lemoine, C., Giacobbe, A., Bonifacino, E., et al. (2021) · Haemophilia · doi:10.1111/hae.14442 · Cited by 18
Tanner, R., Starr, N., Chan, G., Dempsey, E., Heffernan, E., Newman, E., O'Neill, J., Hannan, M. M., Lynch, B., & Joyce, E. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.01.005 · Cited by 18
Reynolds, M. W., Xie, Y., Knuth, K. B., Mack, C. D., Brinkley, E., Toovey, S., & Dreyer, N. A. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s373183 · Cited by 18
Brunner, W. M., Freilich, D., Victory, J. M., Krupa, N. L., Scribani, M., Jenkins, P., Lasher, E. G., Fink, A., Shah, A., Cross, P., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.08.022 · Cited by 21
Wilson, A., Rahai, N., Beck, E. C., Beebe, E., Conroy, B., Esposito, D. B., Govil, P., Kopel, H., Lu, T., Mansi, J. A., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01091-1 · Cited by 17
Fedorovskiy, A. G., Antropov, D. N., Dome, A. S., Puchkov, P. A., Makarova, D. M., Konopleva, M. V., Matveeva, A. M., Panova, E. A., Shmendel, E. V., Maslov, M. A., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050684 · Cited by 19
Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19
Guerrero, A. J., Estirado, A. D., Quirós, J. C., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.07.012 · Cited by 18
Wu, T., Kang, S., Peng, W., Zuo, C., Zhu, Y., Pan, L., Fu, K., You, Y., Yang, X., Luo, X., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.702066 · Cited by 25
Modified Nucleotides for Chemical and Enzymatic Synthesis of Therapeutic RNA
Graczyk, A., Radzikowska‐Cieciura, E., Kaczmarek, R., Pawłowska, R., & Chworoś, A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221014111403 · Cited by 19
Manak, M., Gagnon, L., Phay-Tran, S., Levesque-Damphousse, P., Fabié, A., Daugan, M., Khan, S., Proud, P. C., Hussey, B., Knott, D., et al. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00324-5 · Cited by 18
The current status of COVID-19 vaccines. A scoping review
Rueda-Fernández, M., Melguizo‐Rodríguez, L., Costela-Ruiz, V. J., González‐Acedo, A., Ramos‐Torrecillas, J., & Montes, R. I. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.08.004 · Cited by 21
Spike-based COVID-19 immunization increases antibodies to nucleocapsid antigen
Dobaño, C., Jiménez, A., Rubio, R., Alonso, S., Ramírez‐Morros, A., Vidal, M., Vidal‐Alaball, J., Ruiz‐Comellas, A., García‐Basteiro, A. L., Izquierdo, L., et al. (2021) · Translational research · doi:10.1016/j.trsl.2021.10.004 · Cited by 24
Smith, T. E., & Kister, I. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01117-y · Cited by 21
Fernández-Ciriza, L., González, Á., del Pozo, J. L., Fernández‐Montero, A., Carmona-Torre, F., Carlos, S., Sarasa, M. D. M., & Reina, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-19537-2 · Cited by 22
Hartley, G. E., Fryer, H. A., Gill, P. A., Boo, I., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O’Hehir, R. E., Edwards, E. S. J., & van Zelm, M. C. (2024) · npj Vaccines · doi:10.1038/s41541-024-00919-8 · Cited by 25
On the Influence of Nucleic Acid Backbone Modifications on Lipid Nanoparticle Morphology
An, K., Kurek, D. Z., Mahadeo, M., Zhang, Y., Thewalt, J. L., Cullis, P. R., & Kulkarni, J. A. (2022) · Langmuir · doi:10.1021/acs.langmuir.2c01492 · Cited by 18
Jin, C., Zhang, Y., Li, B., Gao, T., Wang, B., & Hua, P. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101136 · Cited by 28
Gary, E. N., Tursi, N. J., Warner, B. M., Parzych, E. M., Ali, A., Frase, D. M., Moffat, E., Embury‐Hyatt, C., Smith, T. R. F., Broderick, K. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100693 · Cited by 23
Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses
Berber, E., & Ross, T. M. (2024) · Vaccines · doi:10.3390/vaccines12111284 · Cited by 23
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic
Favalli, E. G., Maioli, G., Biggioggero, M., & Caporali, R. F. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1908887 · Cited by 22
Navigating Coronavirus Disease 2019 Vaccination and Uveitis
Jordan, C. A., Townend, S., Allen, N. E., Sims, J. L., McGhee, C. N. J., & Niederer, R. L. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.12.013 · Cited by 20
Pellegrino, R., Pellino, G., Selvaggi, L., Selvaggi, F., Federico, A., Romano, M., & Gravina, A. G. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2120466 · Cited by 19
Protein engineering responses to the COVID-19 pandemic
Hsieh, C., & McLellan, J. S. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102385 · Cited by 17
Moreno, N. F., McAdams, R., Goss, J. A., & Galván, N. T. N. (2022) · Current Transplantation Reports · doi:10.1007/s40472-022-00366-1 · Cited by 21
Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2
Sprute, R., Schumacher, S., Pauls, M., et al. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00358-z · Cited by 18
COVID-19 Variants and Vaccine Development
Zhao, Z., Bashiri, S., Ziora, Z. M., Tóth, I., & Skwarczyński, M. (2024) · Viruses · doi:10.3390/v16050757 · Cited by 27
Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
Gray, A., Martin‐Blais, R., Tobin, N. H., Wang, Y., Brooker, S. L., Li, F., Gadoth, A., Elliott, J. E., Faure-Kumar, E., Halbrook, M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259703 · Cited by 20
In Silico Screening Accelerates Nanocarrier Design for Efficient mRNA Delivery
Henser‐Brownhill, T., Martin, L., Samangouei, P., Ladak, A., Apostolidou, M., Nagel, B., & Kwok, A. (2024) · Advanced Science · doi:10.1002/advs.202401935 · Cited by 20
Immunological changes after COVID-19 vaccination in an HIV-positive patient
Gong, C., Song, X., Li, X., Lu, L., & Li, T. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.08.039 · Cited by 18
Rottenstreich, A., Zarbiv, G., Oiknine‐Djian, E., Vorontsov, O. M., Zigron, R., Kleinstern, G., Porat, S., & Wolf, D. G. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac480 · Cited by 19
Hirota, M., Tamai, M., Yukawa, S., Taira, N., Matthews, M. M., Toma, T., Seto, Y., Yoshida, M., Toguchi, S., Miyagi, M., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04755-9 · Cited by 20
Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies
Wang, J., Ma, L., Chen, Y., Zhou, R., Wang, Q., Zhang, T., Yi, D., Liu, Q., Zhang, Y., Zhang, W., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202302448 · Cited by 21
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.